136 related articles for article (PubMed ID: 17142738)
41. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
[TBL] [Abstract][Full Text] [Related]
42. Treatment with cyclophosphamide supported by various dendritic cell-based vaccines induces diversification in CD4⁺ T cell response against MC38 colon carcinoma.
Wojas-Turek J; Szczygieł A; Kicielińska J; Rossowska J; Piasecki E; Pajtasz-Piasecka E
Int J Oncol; 2016 Feb; 48(2):493-505. PubMed ID: 26648160
[TBL] [Abstract][Full Text] [Related]
43. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.
Zeis M; Siegel S; Wagner A; Schmitz M; Marget M; Kühl-Burmeister R; Adamzik I; Kabelitz D; Dreger P; Schmitz N; Heiser A
J Immunol; 2003 Jun; 170(11):5391-7. PubMed ID: 12759413
[TBL] [Abstract][Full Text] [Related]
44. Immunotherapy with tumor cell lysate-pulsed CD8α+ dendritic cells modulates intra-tumor and spleen lymphocyte subpopulations.
Azadmehr A; Pourfathollah AA; Amirghofran Z; Hassan ZM; Moazzeni SM
Neoplasma; 2013; 60(5):525-32. PubMed ID: 23790171
[TBL] [Abstract][Full Text] [Related]
45. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
[TBL] [Abstract][Full Text] [Related]
46. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
[TBL] [Abstract][Full Text] [Related]
47. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha.
Zhang W; Chen Z; Li F; Kamencic H; Juurlink B; Gordon JR; Xiang J
Immunology; 2003 Feb; 108(2):177-88. PubMed ID: 12562326
[TBL] [Abstract][Full Text] [Related]
48. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
49. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
50. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
51. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
52. Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer.
Kim JH; Majumder N; Lin H; Chen J; Falo LD; You Z
Mol Ther; 2005 Jun; 11(6):941-9. PubMed ID: 15922965
[TBL] [Abstract][Full Text] [Related]
53. Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells.
Saito H; Dubsky P; Dantin C; Finn OJ; Banchereau J; Palucka AK
Breast Cancer Res; 2006; 8(6):R65. PubMed ID: 17129372
[TBL] [Abstract][Full Text] [Related]
54. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge.
Bouwer AL; Saunderson SC; Caldwell FJ; Damani TT; Pelham SJ; Dunn AC; Jack RW; Stoitzner P; McLellan AD
J Immunol; 2014 Mar; 192(5):2514-21. PubMed ID: 24477907
[TBL] [Abstract][Full Text] [Related]
55. Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.
Vo MC; Lee HJ; Kim JS; Hoang MD; Choi NR; Rhee JH; Lakshmanan VK; Shin SJ; Lee JJ
Oncotarget; 2015 Oct; 6(32):33781-90. PubMed ID: 26418952
[TBL] [Abstract][Full Text] [Related]
56. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.
Widenmeyer M; Griesemann H; Stevanović S; Feyerabend S; Klein R; Attig S; Hennenlotter J; Wernet D; Kuprash DV; Sazykin AY; Pascolo S; Stenzl A; Gouttefangeas C; Rammensee HG
Int J Cancer; 2012 Jul; 131(1):140-9. PubMed ID: 21858810
[TBL] [Abstract][Full Text] [Related]
57. Targeting interferon-alpha to dendritic cells enhances a CD8
Graham JP; Authie P; Karolina Palucka A; Zurawski G
Vaccine; 2017 Aug; 35(35 Pt B):4532-4539. PubMed ID: 28743486
[TBL] [Abstract][Full Text] [Related]
58. Development of a Novel CD4
Fernandez-Ruiz D; Lau LS; Ghazanfari N; Jones CM; Ng WY; Davey GM; Berthold D; Holz L; Kato Y; Enders MH; Bayarsaikhan G; Hendriks SH; Lansink LIM; Engel JA; Soon MSF; James KR; Cozijnsen A; Mollard V; Uboldi AD; Tonkin CJ; de Koning-Ward TF; Gilson PR; Kaisho T; Haque A; Crabb BS; Carbone FR; McFadden GI; Heath WR
J Immunol; 2017 Dec; 199(12):4165-4179. PubMed ID: 29084838
[TBL] [Abstract][Full Text] [Related]
59. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
Kim CH; Woo SJ; Park JS; Kim HS; Park MY; Park SD; Hong YK; Kim TG
Immunology; 2007 Dec; 122(4):615-22. PubMed ID: 17645496
[TBL] [Abstract][Full Text] [Related]
60. Preclinical development of HIvax: Human survivin highly immunogenic vaccines.
Hoffmann PR; Panigada M; Soprana E; Terry F; Bandar IS; Napolitano A; Rose AH; Hoffmann FW; Ndhlovu LC; Belcaid M; Moise L; De Groot AS; Carbone M; Gaudino G; Matsui T; Siccardi A; Bertino P
Hum Vaccin Immunother; 2015; 11(7):1585-95. PubMed ID: 26042612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
